Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2026)
Vivos Therapeutics (VVOS) reported Capital Expenditures of $18000.0 for Q1 2026, down 85.25% year-over-year from $122000.0 in Q1 2025, and down 99.59% on a QoQ basis from $4.4 million in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Capital Expenditures data on file, last reported at $18000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 85.25% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 842.67% YoY) and the FY2025 annual result came in at $5.2 million, up 812.85% from the prior year.
- Capital Expenditures declined to $18000.0 in Q1 2026 per VVOS's latest filing, from $4.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.4 million in Q4 2025 and bottomed at -$588000.0 in Q4 2023.
- The 5-year median for Capital Expenditures is $151000.0 (2024), against an average of $396764.7.
- The widest annual swing landed in 2023, when Capital Expenditures sank 394.0%; it then surged 2551.52% in 2025.
- Tracing VVOS's Capital Expenditures over 5 years: stood at $200000.0 in 2022, then slumped by 394.0% to -$588000.0 in 2023, then surged by 128.06% to $165000.0 in 2024, then surged by 2551.52% to $4.4 million in 2025, then slumped by 99.59% to $18000.0 in 2026.
- Per Business Quant, the three latest VVOS Capital Expenditures figures stand at $18000.0 (Q1 2026), $4.4 million (Q4 2025), and -$83000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 399.00 Mn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 166.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 444.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 177.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 64.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -85.46 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 76.60 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 86.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 90.20 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 1.53 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | -83,000.00 |
| Sep 30, 2025 | -83,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 504,000.00 |
| Jun 30, 2022 | 504,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Dec 31, 2021 | -1.90 Mn |
| Dec 31, 2021 | -1.90 Mn |
| Sep 30, 2021 | 441,000.00 |
| Sep 30, 2021 | 441,000.00 |
| Jun 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.31 Mn |
| Mar 31, 2021 | 262,000.00 |
| Mar 31, 2021 | 262,000.00 |
| Dec 31, 2020 | -23,011.00 |
| Dec 31, 2020 | -23,011.00 |
| Sep 30, 2020 | 12,004.00 |
| Sep 30, 2020 | 12,004.00 |
| Jun 30, 2020 | 7,803.00 |
| Jun 30, 2020 | 7,803.00 |
| Mar 31, 2020 | 5,204.00 |
| Mar 31, 2020 | 5,204.00 |